Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study
We prospectively evaluated the diagnostic contribution of 123I-FP-Cit (DAT) and 123I-IBZM (IBZM) SPECT in 29 patients with Parkinson's disease (PD) (74.4±4.2 years) and 28 patients with atypical parkinsonian diseases (APD) (74.3±9.2 years). Twelve had multiple system atrophy (MSA) and 16 progre...
Main Authors: | , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Hindawi Limited
2013-01-01
|
Series: | BioMed Research International |
Online Access: | http://dx.doi.org/10.1155/2013/143532 |
id |
doaj-d6e5a90f19ec47528d147a06033a4e10 |
---|---|
record_format |
Article |
spelling |
doaj-d6e5a90f19ec47528d147a06033a4e102020-11-24T22:19:40ZengHindawi LimitedBioMed Research International2314-61332314-61412013-01-01201310.1155/2013/143532143532Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up StudySusanna Jakobson Mo0Jan Linder1Lars Forsgren2Henrik Holmberg3Anne Larsson4Katrine Riklund5Department of Radiation Sciences, Diagnostic Radiology, Umeå University, 90187 Umeå, SwedenDepartment of Pharmacology and Clinical Neuroscience, Neurology, Umeå University, 90187 Umeå, SwedenDepartment of Pharmacology and Clinical Neuroscience, Neurology, Umeå University, 90187 Umeå, SwedenDepartment of Statistics, Umeå School of Business and Economics, Umeå University, 90187 Umeå, SwedenDepartment of Radiation Sciences, Radiation Physics, Umeå University, 90187 Umeå, SwedenDepartment of Radiation Sciences, Diagnostic Radiology, Umeå University, 90187 Umeå, SwedenWe prospectively evaluated the diagnostic contribution of 123I-FP-Cit (DAT) and 123I-IBZM (IBZM) SPECT in 29 patients with Parkinson's disease (PD) (74.4±4.2 years) and 28 patients with atypical parkinsonian diseases (APD) (74.3±9.2 years). Twelve had multiple system atrophy (MSA) and 16 progressive supranuclear palsy (PSP). Sixteen age-matched healthy controls (HC) were included. DAT and IBZM SPECTs were made at baseline and after 1 year in all PD patients and in 20 (DAT) and 18 (IBZM) of the APD patients, and after 3 years in 22 (DAT) and 17 (IBZM) of the PD patients and in 10 (DAT) and 10 (IBZM) of the APD patients. The relative DAT uptake decrease was faster in PD and PSP than in HC and MSA. In PSP the DAT uptake was lower than in MSA after 1 year but not after 3 years. Baseline IBZM uptake was not significantly different between patients and HC or between PD and APD. One year after initiated dopaminergic treatment the mean IBZM uptake in the MSA patients remained high compared to PSP and after 3 years compared to PD, PSP, and HC. Thus, the pattern of uptake of these ligands over time may be of value in discriminating between these diagnoses.http://dx.doi.org/10.1155/2013/143532 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Susanna Jakobson Mo Jan Linder Lars Forsgren Henrik Holmberg Anne Larsson Katrine Riklund |
spellingShingle |
Susanna Jakobson Mo Jan Linder Lars Forsgren Henrik Holmberg Anne Larsson Katrine Riklund Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study BioMed Research International |
author_facet |
Susanna Jakobson Mo Jan Linder Lars Forsgren Henrik Holmberg Anne Larsson Katrine Riklund |
author_sort |
Susanna Jakobson Mo |
title |
Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study |
title_short |
Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study |
title_full |
Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study |
title_fullStr |
Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study |
title_full_unstemmed |
Pre- and Postsynaptic Dopamine SPECT in Idiopathic Parkinsonian Diseases: A Follow-Up Study |
title_sort |
pre- and postsynaptic dopamine spect in idiopathic parkinsonian diseases: a follow-up study |
publisher |
Hindawi Limited |
series |
BioMed Research International |
issn |
2314-6133 2314-6141 |
publishDate |
2013-01-01 |
description |
We prospectively evaluated the diagnostic contribution of 123I-FP-Cit (DAT) and 123I-IBZM (IBZM) SPECT in 29 patients with Parkinson's disease (PD) (74.4±4.2 years) and 28 patients with atypical parkinsonian diseases (APD) (74.3±9.2 years). Twelve had multiple system atrophy (MSA) and 16 progressive supranuclear palsy (PSP). Sixteen age-matched healthy controls (HC) were included. DAT and IBZM SPECTs were made at baseline and after 1 year in all PD patients and in 20 (DAT) and 18 (IBZM) of the APD patients, and after 3 years in 22 (DAT) and 17 (IBZM) of the PD patients and in 10 (DAT) and 10 (IBZM) of the APD patients. The relative DAT uptake decrease was faster in PD and PSP than in HC and MSA. In PSP the DAT uptake was lower than in MSA after 1 year but not after 3 years. Baseline IBZM uptake was not significantly different between patients and HC or between PD and APD. One year after initiated dopaminergic treatment the mean IBZM uptake in the MSA patients remained high compared to PSP and after 3 years compared to PD, PSP, and HC. Thus, the pattern of uptake of these ligands over time may be of value in discriminating between these diagnoses. |
url |
http://dx.doi.org/10.1155/2013/143532 |
work_keys_str_mv |
AT susannajakobsonmo preandpostsynapticdopaminespectinidiopathicparkinsoniandiseasesafollowupstudy AT janlinder preandpostsynapticdopaminespectinidiopathicparkinsoniandiseasesafollowupstudy AT larsforsgren preandpostsynapticdopaminespectinidiopathicparkinsoniandiseasesafollowupstudy AT henrikholmberg preandpostsynapticdopaminespectinidiopathicparkinsoniandiseasesafollowupstudy AT annelarsson preandpostsynapticdopaminespectinidiopathicparkinsoniandiseasesafollowupstudy AT katrineriklund preandpostsynapticdopaminespectinidiopathicparkinsoniandiseasesafollowupstudy |
_version_ |
1725778089673228288 |